Clinical Trial Update: Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of INGN 241 gene therapy in patients with in-transit malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• INGN 241 (INGN 241)

Snippet

Sponsor: Introgen Therapeutics | Conditions: Malignant Melanoma, Neoplasm Metastasis | Phase 2 | Status: UNKNOWN